Price comparison of high-cost pharmaceuticals 2017 (German only)

Peter Schneider, Sabine Vogler, Nina Zimmermann, Martin Zuba (Gesundheit Österreich, GÖG)

Continuous monitoring and analysis of medicine prices support policy-makers in strengthening and further developing pharmaceutical pricing policies. High-cost medicines, i.e. those medicines that account for high public pharmaceutical expenditure, are of particular interest for policy-makers. Against this backdrop, the study aims to analyse Austrian prices of high-cost medicines in comparison to other European Union (EU) Member States.

Read more

Collaborating Across Europe to Ensure Fair, Accessible, and Sustainable Healthcare

Who We Are

About

Participating Countries

Organisation

FAQ

What We Do

News

Activities

Data

Publications

Webinars

Get Involved

Authorities

Researchers

Stakeholders

Citizens

Newsletter

Contact

The EURIPID collaboration is currently funded by an annual contribution fee of the participants and – for defined tasks and deliverables – a grant of the EU.

This website is part of the project ’826652 Euripid’ which is co-funded by the European Union’s Health Programme (2014-2020).

The content of this website represents the views of the author only and is his/her sole responsibility; it cannot be considered to reflect the views of the European Commission and/or the Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) or any other body of the European Union. The European Commission and the Agency do not accept any responsibility for use that may be made of the information it contains.

© Copyright – EURIPID

Newsletter FAQ Privacy Policy
International price comparison of pharmaceuticals 2017 – a volume based analysis...The implications of external price referencing on pharmaceutical list prices...